Cidara Therapeutics’ business outlook improved substantially on June 23 after releasing pre-market Phase IIb data for its non-vaccine seasonal influenza prevention agent showing better prophylaxis capabilities than usually seen with flu shots. The San Diego firm said on a same-day call that it hopes to convene end-of-Phase II talks with the US Food and Drug Administration soon to plan a pivotal study.
Key Takeaways
- Cidara unveiled Phase IIb data for its non-vaccine flu prevention agent CD388 showing statistical significance for preventive efficacy at three tested doses.
The positive topline Phase IIb data for CD388, a drug-Fc conjugate (DFC), provide validation for Cidara’s change of course in...